Literature DB >> 1472124

Ankylosing spondylitis in Rochester, Minnesota, 1935-1989. Is the epidemiology changing?

L D Carbone1, C Cooper, C J Michet, E J Atkinson, W M O'Fallon, L J Melton.   

Abstract

OBJECTIVE: To determine trends in the incidence and clinical presentation of ankylosing spondylitis first diagnosed between 1935 and 1989 among residents of Rochester, Minnesota, and in the survival of the patients.
METHODS: Population-based descriptive study.
RESULTS: The overall age- and sex-adjusted incidence rate was 7.3 per 100,000 person-years (95% confidence interval 6.1-8.4). The rate tended to decline between 1935 and 1989, but there was little change in the age at symptom onset or diagnosis over the 55-year study period. Overall survival was not decreased up to 28 years following diagnosis.
CONCLUSION: These data indicate that there is a constancy in the epidemiologic characteristics of ankylosing spondylitis and suggest that previously study results indicating changes may have been due to biases in patient selection and study design.

Entities:  

Mesh:

Year:  1992        PMID: 1472124     DOI: 10.1002/art.1780351211

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  35 in total

1.  Seronegative spondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study.

Authors:  P Trontzas; A Andrianakos; S Miyakis; K Pantelidou; E Vafiadou; V Garantziotou; C Voudouris
Journal:  Clin Rheumatol       Date:  2005-04-29       Impact factor: 2.980

Review 2.  Spondyloarthritis with onset after age 45.

Authors:  Ignazio Olivieri; Salvatore D'Angelo; Angela Padula; Pietro Leccese; Carlo Palazzi
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

3.  The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.

Authors:  Cynthia S Crowson; Eric L Matteson; Elena Myasoedova; Clement J Michet; Floranne C Ernste; Kenneth J Warrington; John M Davis; Gene G Hunder; Terry M Therneau; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2011-03

Review 4.  The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases.

Authors:  Hilal Maradit Kremers; Elena Myasoedova; Cynthia S Crowson; Guergana Savova; Sherine E Gabriel; Eric L Matteson
Journal:  Rheumatology (Oxford)       Date:  2010-07-13       Impact factor: 7.580

5.  Demographic, clinical, and laboratory features of Turkish patients with late onset ankylosing spondylitis.

Authors:  Ahmet Karaarslan; Hatice Yilmaz; Hakan Aycan; Mehmet Orman; Senol Kobak
Journal:  Bosn J Basic Med Sci       Date:  2015-07-22       Impact factor: 3.363

6.  Mortality in patients with ankylosing spondylitis in Argentina.

Authors:  Emilio Andres Buschiazzo; Emilce Edith Schneeberger; Fernando Andres Sommerfleck; Cesar Ledesma; Gustavo Citera
Journal:  Clin Rheumatol       Date:  2016-07-04       Impact factor: 2.980

7.  Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting.

Authors:  Jeffrey R Curtis; Leslie R Harrold; Maryam M Asgari; Atul Deodhar; Craig Salman; Joel M Gelfand; Jashin J Wu; Lisa J Herrinton
Journal:  Perm J       Date:  2016-07-29

8.  Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study.

Authors:  Joseph J Keller; Jung-Lung Hsu; Shiue-Ming Lin; Chia-Chi Chou; Li-Hsuan Wang; Jui Wang; Chyi-Huey Bai; Hung-Yi Chiou
Journal:  Rheumatol Int       Date:  2013-12-10       Impact factor: 2.631

9.  Annual incidence of inflammatory joint diseases in a population based study in southern Sweden.

Authors:  M K Söderlin; O Börjesson; H Kautiainen; T Skogh; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.